Get the Stockscreener App
127.12
0.07%
0.09
After Hours:
127.12
Intra Cellular Therapies Inc stock is traded at $127.12, with a volume of 1.80M.
It is up +0.07% in the last 24 hours and up +55.44% over the past month.
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.
See More
Previous Close:
$127.03
Open:
$127.08
24h Volume:
1.80M
Relative Volume:
0.84
Market Cap:
$13.51B
Revenue:
$612.78M
Net Income/Loss:
$-86.37M
P/E Ratio:
-146.11
EPS:
-0.87
Net Cash Flow:
$-62.91M
1W Performance:
+0.09%
1M Performance:
+55.44%
6M Performance:
+62.62%
1Y Performance:
+81.37%
1-Day Range:
$127.01
$127.26
1-Week Range:
$126.88
$127.36
52-Week Range:
$62.78
$128.00
Intra Cellular Therapies Inc Stock (ITCI) Company Profile
Name
Intra Cellular Therapies Inc
Sector
Phone
(646) 440-9333
Address
135 ROUTE 202/206, BEDMINSTER, NY
Compare ITCI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ITCI
Intra Cellular Therapies Inc
|
127.12 | 13.51B | 612.78M | -86.37M | -62.91M | -0.87 |
|
ZTS
Zoetis Inc
|
174.12 | 78.56B | 9.15B | 2.43B | 2.31B | 5.32 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.61 | 43.15B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
9.51 | 43.00B | 14.26B | 1.55B | 0 | 0.3383 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.29 | 19.59B | 16.54B | -1.64B | 749.00M | -1.45 |
|
NBIX
Neurocrine Biosciences Inc
|
150.51 | 15.24B | 2.24B | 385.90M | 440.10M | 3.73 |
Intra Cellular Therapies Inc Stock (ITCI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-31-25 | Downgrade | Canaccord Genuity | Buy → Hold |
| Sep-06-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-03-24 | Initiated | Robert W. Baird | Outperform |
| Dec-11-23 | Initiated | TD Cowen | Outperform |
| Apr-20-23 | Initiated | Morgan Stanley | Overweight |
| Aug-22-22 | Downgrade | Goldman | Buy → Neutral |
| Jul-07-22 | Initiated | Mizuho | Buy |
| Jun-14-22 | Initiated | UBS | Buy |
| Apr-22-22 | Initiated | Piper Sandler | Neutral |
| Feb-16-22 | Initiated | Goldman | Buy |
| Sep-23-21 | Initiated | Needham | Buy |
| Dec-15-20 | Initiated | BofA Securities | Buy |
| Dec-10-20 | Initiated | Goldman | Buy |
| Feb-20-20 | Initiated | Evercore ISI | Outperform |
| Jan-31-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-24-19 | Reiterated | Canaccord Genuity | Buy |
| Aug-12-19 | Initiated | Jefferies | Buy |
| Feb-26-18 | Initiated | JP Morgan | Overweight |
| Feb-08-18 | Initiated | RBC Capital Mkts | Outperform |
| Dec-15-17 | Initiated | Canaccord Genuity | Buy |
| Nov-08-17 | Upgrade | SunTrust | Hold → Buy |
| Sep-07-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Aug-30-17 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Aug-24-17 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Aug-23-17 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| May-02-17 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| May-02-17 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| May-01-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Dec-16-16 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-29-16 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-29-16 | Downgrade | SunTrust | Buy → Neutral |
View All
Intra Cellular Therapies Inc Stock (ITCI) Latest News
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Sees Significant Growth in Short Interest - MarketBeat
UBS Adjusts Price Target on Intra-Cellular Therapies to $132 From $87, Maintains Neutral Rating - Marketscreener.com
Calamos Advisors LLC Sells 3,952 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Bought by China Universal Asset Management Co. Ltd. - MarketBeat
Intra-Cellular Therapies (NASDAQ:ITCI) Downgraded by Canaccord Genuity Group to Hold - MarketBeat
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LGTY, ENFN, ITCI, SSTK on Behalf of Shareholders - GlobeNewswire Inc.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
KBC Group NV Boosts Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - Defense World
StockNews.com Initiates Coverage on Intra-Cellular Therapies (NASDAQ:ITCI) - MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Short Interest Up 5.3% in January - Defense World
Canaccord cuts Intra-Cellular stock rating, raises target to $132 - MSN
Intra-Cellular Therapies (NASDAQ:ITCI) Cut to “Hold” at Canaccord Genuity Group - Defense World
Moody Aldrich Partners LLC Cuts Stock Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
R Squared Ltd Takes $205,000 Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
SG Americas Securities LLC Grows Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Canaccord Genuity Downgrades Intra-Cellular Therapies to Hold From Buy, Adjusts Price Target to $132 From $119 - Marketscreener.com
Intra-Cellular Therapies (NASDAQ:ITCI) Now Covered by StockNews.com - Defense World
SG Americas Securities LLC Buys 8,673 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - Defense World
Why Intra-Cellular Therapies (ITCI) Is Skyrocketing Now - MSN
Merit Financial Group LLC Buys New Shares in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
(ITCI) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Why Intra-Cellular Therapies, Inc. (ITCI) Is Skyrocketing Now - MSN
Cantor Fitzgerald Estimates ITCI FY2025 Earnings - Defense World
Demystifying Intra-Cellular Therapies: Insights From 6 Analyst Reviews - Benzinga
J&J Says Deals Likely to Shrink After $14.6B Intra-Cellular Buy - BioSpace
Intra-Cellular Therapies (NASDAQ:ITCI) Given "Sector Perform" Rating at Royal Bank of Canada - MarketBeat
J&J’s Intra-Cellular deal could signal more mega-mergers for 2025 - Chemistry World
Barlow Wealth Partners Inc. Purchases Shares of 2,200 Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Johnson & Johnson acquires Intra-Cellular Therapies - Pf Media
Research Analysts Issue Forecasts for ITCI FY2025 Earnings - MarketBeat
RBC Capital cuts Intra-Cellular stock rating, hikes target to $132 - MSN
Intra-Cellular Therapies Stock Pops as Johnson & Johnson Buys Firm for $14.6B - MSN
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Enfusion, Inc. (NYSEENFN), Intra-Cellular Therapies, Inc. (NasdaqITCI), H&E Equipment Services, Inc. (NasdaqHEES), Shutterstock, Inc. (NYSE - GlobeNewswire Inc.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LTRPA, OMIC, ITCI, CCNE on Behalf of Shareholders - Morningstar
Intra Cellular Therapies Inc Stock (ITCI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.46%
0.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):